Health
Drug Compound Targets Weakness in Advanced Prostate Cancer – Technology Networks
A new study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted using the compound thymoquinone.
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene. Led by researchers at Kanazawa University, the study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted. SUCLA2-deficient prostate cancers represent a significant fraction of those resistant to hormone therapy or metastatic, and a new therapeutic option for this disease would have immense benefits for patient…
-
Business24 hours agoThese ASX 200 shares could rise 50% to 60%
-
General23 hours agoAustralia’s Myanmar community mourns earthquake losses
-
Noosa News22 hours agoHow to get the most from potted citrus and when they’ll fruit
-
General22 hours agoPeter Dutton partially walks back public service work-from-home vow